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Abst rac t
Background and purpose: A unique molecular and/or cellu-
lar marker for meningiomas, the most common intracranial
tumours, has not been identified yet.
Material and methods: We investigated the co-localization frac-
tion of CD133/Ki-67 in meningioma tissue array slide com-
posed of 80 meningioma tissue samples of various histologi-
cal variants. CD133 – a cell membrane stem cell marker – was
previously proved to be associated with the initiation and pro-
gression of intracerebral gliomas and medulloblastomas.
Results: Immunohistochemical co-localization of CD133/
Ki-67 was significantly higher in fibroblastic variant than in
meningothelial and transitional subtypes. However, since there
were only 3 atypical and 1 malignant meningioma spots in the
tumour tissue array slide, it is difficult to draw a firm conclusion
regarding the actual co-localization percentage and persistence
of CD133/Ki-67 in atypical and malignant meningiomas.
Conclusions: Far higher co-staining percentage of CD133/
Ki-67 in fibroblastic meningioma samples compared to
meningothelial subtype, a histological meningioma variant, 
architectonically resembling the non-neoplastic meningeal cells,
gave us the impression that CD133 may play a role in the for-
mation and progression of fibroblastic meningioma variants.
The double immunostaining of CD133 and Ki-67 favours a significant 
co-localization pattern in fibroblastic subtype of meningiomas 
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St reszczenie
Wstêp i cel pracy: Nie okreœlono dot¹d unikalnego znaczni-
ka molekularnego lub komórkowego dla oponiaków, naj-
czêstszych guzów wewn¹trzczaszkowych. Wczeœniej wykazano,
¿e CD133 – znacznik b³ony komórkowej komórek macie-
rzystych – jest zwi¹zany z zapocz¹tkowaniem, a tak¿e wzro-
stem wewn¹trzczaszkowych glejaków i rdzeniaków p³odowych.
Materia³ i metody: Zbadano odsetek wspó³lokalizacji
CD133/Ki-67 w zestawach macierzy tkankowych oponiaków,
z³o¿onych z próbek 80 rozmaitych odmian histologicznych opo-
niaków.
Wyniki: Immunohistochemiczna wspó³lokalizacja CD133 
i Ki-67 by³a stwierdzana istotnie czêœciej w podtypie w³ók -
nistym oponiaka ni¿ w podtypach meningotelialnym lub 
przejœ ciowym. Ze wzglêdu na ma³¹ liczbê preparatów opo-
niaków atypowych (3) oraz z³oœliwych (1) w badanej macie-
rzy tkankowej trudno wyci¹gn¹æ jednoznaczne wnioski do-
tycz¹ce rzeczywistego odsetka wspó³lokalizacji i utrzymywania
siê CD133/Ki-67 w oponiakach atypowych i z³oœliwych.
Wnioski: Znacz¹co wiêkszy odsetek wspólnie wystêpuj¹cej 
reaktywnoœci CD133/Ki-67 w preparatach oponiaka w³ókni-
stego w porównaniu z podtypem meningotelialnym, którego
archi tektonika przypomina nienowotworowe komórki opon,
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Introduction 
Meningiomas, the most common intracranial tumours,
constitute almost one-third of all brain tumours. They are
thought to be of neuroectodermal origin based on the strik-
ing ultrastructural and histological resemblance to arach-
noid cells [1-3]. Meningiomas were defined well cyto-
genetically but they are poorly understood molecularly.
Thus, histopathological grading of meningiomas does not
necessarily predict its clinical course, particularly in aty -
pical meningiomas [4]. Additionally, recent findings in
molecular genetics provide strong evidence that menin-
giogenesis is a dynamic process with tumour suppressor
NF-2 gene deletion on chromosome 22 and several 
other genetic aberrations including the deletion of the
INK4a-ARF locus [5]. In this regard, cellular origin of
meningiomas with a unique molecular marker still
needs to be clarified.
For this purpose, in a meningioma tissue array con-
sisting of 80 meningiomas of various histopathological
subsets, we investigated the co-localization pattern of
CD133, a cell-surface antigen – a proposed molecular
signature for meningioma cells with Ki-67 nuclear anti-
gen which is expressed in dividing cells in all phases of
the cell cycle except G0. Even though the exact biolo -
gical function of CD133, a cell-surface antigen, is not
known, it is a marker for stem and progenitor cells.
CD133 was also widely expressed in cancers, including
some leukaemias and brain tumours, mostly in gliomas
and medulloblastomas. According to our hypothesis,
meningioma cells with Ki-67 expression may have the po-
tential to be the pluripotent meningioma initiating cells
since Ki-67 antigen is mostly expressed in dividing cells
and CD133, a cell-surface antigen, was proposed as a mo -
lecular marker for these candidate meningioma-initiat-
ing cells. Thus, for the first time in the literature, co-
expression fraction and consistency of CD133 and 
Ki-67 in various meningioma subtypes were investigat-
ed immunohistochemically in our study. 
Material and methods 
The efficacy of the below-explained double immu -
nostaining procedure was confirmed in several human
meningioma paraffin slides (WHO grade I meningioma)
with a negative control prior to proceeding to the immu -
nostaining of the meningioma tissue array slide (Fig. 1).
For CD133 immunohistochemistry, paraffin slide con-
sisting of 80 meningioma tissue samples (meningioma of
central nerve tissue array # MG801, US Biomax, Inc.,
1100, TaftSt. Rockville, MD 20850, USA) was deparaf-
finized and blocked for endogenous peroxidase activity with
methanol containing 3% H2O2 for 15 min and for non-
specific binding with universal blocking reagent (BioGenex,
San Ramon, CA, USA) for 7 min at room temperature.
Anti-mouse CD133 (Cat # 14-1331-80, eBioscience, Inc,
San Diego, CA, USA) diluted in dilution buffer (1/100)
was applied for 1 hour at room temperature in a humidi-
fied chamber. After several washes in PBS, the section was
incubated with biotinylated goat anti-mouse IgG secondary
antibody (1/400 dilution, Vector Lab., Burlingame, CA,
USA) for 45 min followed by LSAB streptavidin-peroxi-
dase complex (Dako, Carpinteria, CA, USA) incubation
for 30 min and was rinsed with PBS. Antibody complex was
visualized by incubation with diaminobenzidine (DAB) 
chromogen (BioGenex). After several washes in PBS, the
section was incubated with a Ki-67 (Cat # RM-9106-S0;
ThermoScientific, Fremont, CA, USA) rabbit monoclo-
nal antibody (1/100 dilution) overnight at 4°C. Following
the washing steps in PBS, the section was incubated with
anti-rabbit biotinylated goat anti-mouse IgG secondary 
antibody (1/400 dilution, Vector Lab. Burlingame, CA,
USA) for 45 min followed by LSAB streptavidin-peroxi-
dase complex (Dako, Carpinteria, CA, USA) incubation
for 30 min and rinsed with PBS. Antibody complex was 
visualized by incubation with 3-amino-9-ethylcarbazole
(AEC) chromogen (Thermoscientific). The section was
counterstained with Mayer’s haematoxylin (Dako), dehy-
drated, mounted and examined by a Zeiss-Axioplan
Baki S. Albayrak, Ozgur Ismailoglu, Gamze Tanriover, Eralp N. Cetinalp, Necdet Demir   
The persistency and the validity of this finding need to be ver-
ified by further histopathological and molecular research in
order to clarify the possible role of CD133 in meningiogen-
esis. 
Key words: meningioma, fibroblastic, CD133, Ki-67, tissue
array, co-localization.  
sprawia wra¿enie, ¿e CD133 mo¿e odgrywaæ rolê w powsta-
waniu i rozwoju oponiaków w³óknistych. Trafnoœæ tego 
spostrze¿enia wymaga weryfikacji w dalszych badaniach 
histopatologicznych i molekularnych w celu wyjaœnienia
mo¿liwej roli CD133 w powstawaniu oponiaków.
S³owa kluczowe: oponiak, w³óknisty, CD133, Ki-67, macierz
tkankowa, wspó³lokalizacja.
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The double immunostaining of CD133 and Ki-67 in meningiomas
Fig. 1. Human meningioma paraffin trial slide double stained with CD133 and Ki-67. A, B) Total area 10×, C) negative control 20×, D) 20×, E) 40×, 
F-N) 100× cell staining, arrows: double staining (CD133/Ki-67), arrowheads: CD133 staining, CD133 cytoplasmic staining with DAB (brown), Ki-67 nuclear
staining with AEC (red) 
Meningioma Number and Mean % of
subtype percentage of each co-localization
meningioma (magnification ×40)
subtype 
Meningothelial 17 (22%) 1.50%
Fibroblastic 37 (49%) 3.67%*
Transitional 14 (18.5%) 1.60%
Psammomatous 2 (2.6%) 0.25%
Microcystic 2 (2.6%) 0.0%
Atypical 3 (4%) 1.30%
Malignant 1 (1.3%) 1.50%
(papillary type)
Table 1. Number of specific meningioma subtypes and the mean
percentage of CD133 and Ki-67 expression for each meningioma group
*Mean percentage of co-localization is significantly higher in fibroblastic meningioma subtype
than the other subtypes 
(Oberkochen, Germany) microscope and the co-localiza-
tion ratio of CD133 and Ki-67 staining was calculated us-
ing a 40× magnification high-power field for each menin-
gioma tissue sample.
Mean fraction of co-localization in various menin-
gioma subtypes was analysed applying a non-parame tric
Kruskal-Wallis test with a significance level of 0.05 (SPSS
15.0 software).    
Results 
Immunostaining of CD133 and Ki-67 was satisfac-
torily positive in 76 of 80 (95%) meningioma tissues sam-
ples in the tumour tissue array slide. Number of tumour
subtypes and the mean percent of co-localization are de-
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picted in Table 1. Co-localization fraction was significantly
higher in fibroblastic meningioma subtypes than those
of other histological variants including meningothelial,
transitional, psammomatous, microcytic, atypical, and ma-
lignant (papillary) types (Figs. 2-4) (p < 0.0001).
Discussion
Although all meningioma subsets are thought to be
derived from meningothelial cells, they display a wide
spectrum of histological variants. The WHO classification
in 2007 reported that meningothelial, fibrous and tran-
sitional (combination of meningothelial and fibroblastic
appearance) subtypes are the most frequent subtypes.
While grade I meningiomas (meningothelial, fibroblastic,
transitional, psammomatous, angiomatous, microcystic,
secretory, lymphoplasmacyte-rich, metaplastic) are gene -
rally treated satisfactorily, grade II (atypical, chordoid and
clear cell tumours) and grade III (anaplastic, papillary,
and rhabdoid tumours) subtypes tend to behave more 
aggressively with higher recurrence rates [4,6]. Menin -
gothelial (also known as syncytial meningioma) is the most
common variant and is composed of cells with aberrant
borders. Fibrous tissue is characteristically absent and
whorls and psammoma bodies are less frequently en-
countered in meningothelial tumours. The meningioma
cells exhibit round to oval nuclei and variable numbers
of nuclear-cytoplasmic inclusions surrounded by mar-
ginated chromatin. Glycogen containing inclusions can
also be observed in this variant, giving the classical
ground-glass appearance. Fibrous meningiomas are
less common than the meningothelial variant and con-
sist of elongated spindle cells with a variable degree of col-
lagen. Nuclei are often hyperchromatic and more elon-
gated than those of the meningothelial and transitional 
variants. Transitional meningiomas are the intermediate
subtype between meningothelial and fibrous patterns. 
Generally, lobules appear syncytial with the elongated 
fibrous cells located in the periphery. Overall, the most
reliable diagnostic marker for meningioma is cell-surface
immunoreactivity for epithelial membrane antigen
(EMA) with more marked staining in meningothelial and
transitional lesions than in fibrous tumours. Diffuse im-
munoreactivity for vimentin is also seen in all variants of
meningioma. Cytokeratin reactivity is typically observed
in secretory meningiomas. However, regarding the cell-
surface markers, only CD44 expression in meningioma
cells was extensively investigated and it was agreed that
the over-expression of CD44 was associated with increased
migration ability and anaplasia in meningioma cells
[7,8]. Sainio et al. [9] demonstrated the co-localization
of the NF2 gene product merlin protein with CD44 and
the interaction of CD44 with cytoskeleton via ezrin, radi -
xin, and moesin proteins – structural relatives of merlin
protein. Even though the data on CD44 function in
meningioma cells support the idea that CD44 contributes
to the invasiveness and anaplasia of meningiomas, some
authors have claimed that CD44 may have a biphasic 
effect on meningioma cells – that is, CD44 promotes 
migration of meningiomas cells in low concentrations,
whereas it causes inhibition in higher concentrations [8].
Notably, it is evident that CD44, as a cell surface mark-
er, has interactions with small cellular membrane proteins
such as ezrin, moesin, and merlin, which is encoded 
by the NF2 gene, a tumour suppressor gene, and its bial-
lelic inactivation was detected in more than half of me -
ningiomas [9,10].
To our knowledge, there is no single report regard-
ing the expression pattern of CD133 in meningioma cells.
However, numerous studies have demonstrated that only
CD133-positive glioblastoma multiforme (GBM) cells
have tumour-initiating potential. Cancer stem cells in
gliomas were first proposed by Singh et al. [11] and the
authors proved that only CD133-positive glioma cells have
the self-renewal and self-propagating capacity. Addi-
tionally, cancer stem cells derived from GBM are capa-
ble of recapitulating original tumours when transplant-
ed into nude mice. Taken together, CD133 plays
a crucial role in GBM initiation and progression. In our
study, the CD133/Ki-67 co-expression fraction was
significantly higher in fibroblastic meningiomas than in
other meningioma variants. However, since there were
only 3 atypical and 1 malignant meningioma spots in the
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Fig. 2. Fibroblastic meningioma spots in tissue micro-array slide double
stained with CD133 and Ki-67
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The double immunostaining of CD133 and Ki-67 in meningiomas
Fig. 3. Meningothelial meningioma spots in tissue micro-array slide double stained with CD133 and Ki-67
tumour tissue array slide, it is difficult to draw a conclusion
regarding the actual co-localization percentage and
persistence of CD133/Ki-67 in atypical and malignant
meningiomas. Nevertheless, the far higher co-staining
percentage of CD133/Ki-67 in fibroblastic meningioma
samples compared to meningothelial subtype, a histo-
logical meningioma variant, architecturally resembling
the non-neoplastic meningeal cells, gave us the impres-
sion that CD133 may play a role in the formation and pro-
gression of fibroblastic meningioma variants.
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Fig. 4. Transitional (mixed) meningioma spots in tissue micro-array slide double stained with CD133 and Ki-67. CD133 cytoplasmic staining with DAB 
(brown in colour) and Ki-67 nuclear staining with AEC (red in colour)
Conclusions
1. The immunohistopathologically demonstrated per-
sistent and significant co-staining pattern of CD133/
Ki-67 in fibroblastic meningioma cells still needs to be
verified in various tumour samples obtained from pa-
tients with meningiomas.
2. The further investigation of the possible role of
CD133 in meningiogenesis may contribute to the un-
derstanding of the diversity of meningiomas at the cel-
lular and molecular level.  
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